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The extracts of Salacia reticulata (Salacia extract), a plant that has been used for the treatment of early diabetes, rheumatism
and gonorrhea in Ayurveda, have been shown to have an anti-obesity eﬀect and suppress hyperglycemia. In this study, the
eﬀects of Salacia extract on various symptoms of metabolic disorder were investigated and compared using these TSOD mice
and non-obese TSNO mice. Body weight, food intake, plasma biochemistry, visceral and subcutaneous fat (X-ray and CT),
glucose tolerance, blood pressure and pain tolerance were measured, and histopathological examination of the liver was carried
out. A signiﬁcant dose-dependent decline in the gain in body weight, accumulation of visceral and subcutaneous fat and an
improvement of abnormal glucose tolerance, hypertension and peripheral neuropathy were noticed in TSOD mice. In addition,
hepatocellular swelling, fatty degeneration of hepatocytes, inﬂammatory cell inﬁltration and single-cell necrosis were observed
on histopathologicalexamination of the liver in TSOD mice. Salacia extract markedly improved these symptoms upon treatment.
Basedontheaboveresults, it isconcludedthatSalacia extract hasremarkablepotentialto preventobesityandassociatedmetabolic
disorders including the development of metabolic syndrome.
1.Introduction
Ayurvedic medicine is an ancient system of healthcare that
is native to the Indian subcontinent. It is presently in daily
use by millions of people in India, Nepal and Sri Lanka [1].
Salacia reticulata is a climbing plant in the Hippocrateaceae
family that has been used traditionally in Indian Ayurvedic
medicine and is said to be eﬀective for the prevention
and treatment of diabetes, rheumatism, gonorrhea and
skin diseases [2]. The major phytochemical components of
SalaciaincludeTriterpenes[3]suchasantileukemicIsoigues-
terin [4], Aldose reductase and α-glucosidase inhibitors,
such as kotalanin 16-acetate [5], Kotalanol [2] and potent
antioxidant, quinine methides [6], polyphenol constituents
with α-glucosidase and aldose reductase inhibitory activities,
Mangiferin [7, 8] and potent α-glucosidase inhibitor, Sala-
cinol [9, 10]. There are evidencesto suggest that the member
of Salacia family are eﬃcacious for treatment of metabolic
disorders, obesity [11], hyperinsulinemia [12], cardiac lipid
metabolism [13]a n dc a r d i a ch y p e r t r o p h y[ 14], and it is
expected that the salacia family will be eﬃcacious in the
treatment of metabolic disorders. In contrast, Ratnasooriya
et al. reported that a large dose of S. reticulata root extract
could be hazardous to successful pregnancy in women [15].
In this study, we have investigated the preventive eﬀects
of S. reticulata on various disease states (diabetes, hyper-
lipidemia, hypertension and diabetic peripheral neuropathy)
that accompany metabolic disorders. We focused on the
visceral fat accumulation using a model animal, TSOD
(Tsumura, Suzuki, Obese, Diabetes) mice, which are known2 Evidence-Based Complementary and Alternative Medicine
to develop disease states similar to human metabolic disor-
dersincludingvisceral fat accumulation,glucose intolerance,
hyperlipidemia,hypertension, hyperinsulinemia andperiph-
eral neuropathy [16].
2.Methods
Male TSOD mice [16–21] and male TSNO (Tsumura
Suzuki Non-Obese) mice were used (Institute of Animal
Reproduction, Ibaragi). TSNO mice, produced from the
same ancestors as TSOD mice, do not develop symptoms
such as visceral fat accumulation, insulin resistance, glucose
and lipid metabolism disorders and hypertension and were
usedascontrolanimals [16–21].TSODandTSNOmicewere
purchased at the age of 3 weeks, and the experiments were
started using 4-week-old mice, after 1 week of acclimation.
All animals were handled in accordance with the
guidelines of the NRC, and this study was approved by
the experimental animal ethics committee in Musashino
University.
An extract of S. reticulata (available as extract powder.
Kothalahim Japan Co., Ltd, Tokyo), identiﬁed by Srilanka
Indigenous Medicine Exporters & Manufacturers Associa-
tion, was further treated by adding branched cyclodextrin
(Isoelite) to a hot-water suspension of the extract. The
solvent was evaporated at low than 40◦C and the remaining
solution was spray-dried to obtain Salacia extract. The study
feed was prepared by mixing the powder feed MF (Oriental
Yeast Co., Ltd., Chiba, Japan) with Salacia e x t r a c ta ta
concentrationof 1.0% or 3.0%.The three-dimensional high-
performance liquidchromatography (HPLC)chromatogram
of the extract powder is shown in Figure 1. The polyphenol
content, determined by the colorimetric method (Folin-
Ciocalteu method), was 7.9%. The mangiferin content was
0.6% as determined by HPLC, using a Wakosil-II5C18AR
column(Mobilephase:methanol and1%aceticacid(10:90)
as the mobile phase, detection at a wavelength of 360nm, a
column temperature of 35◦C and a ﬂow rate of 1mL/min)
( W a k oP u r eC h e m i c a lI n d u s t r i e s ,L t d . ,O s a k a ,J a p a n ) .
2.1. Mode of Administration. After acclimation (1 week),
TSODandTSNOmiceweredividedintothreegroupssothat
the mean body weight of each group was uniform. Animals
were allocated into one of the following groups:
(1) TSOD mice groups:
(a) Powder-fed MF group (TSOD control group),
(b) 1.0% Salacia extract powder-treatment group
(1% SR-TSOD group), and
(c) 3.0% Salacia extract powder-treatment group
(3% SR-TSOD group).
(2) TSNO mice groups:
(a) Powder-fed MF group (TSNO control group),
(b) 1.0% Salacia extract powder-treatment group
(1% SR-TSNO group), and
(c) 3.0% Salacia extract powder-treatment group
(3% SR-TSNO group).
Control groups were given ad libitum powder-feed MF from
a feeder for 8 weeks.
2.2. Food Intake. During the experiment, animals were
given tap water ad libitum for drinking, and were kept
at a temperature of 23 ± 1◦C and a relative humidity of
55 ± 5%, with a 12h light-dark cycle with light time from
8:00 to 20:00. Animals were kept for 2 months. Food
intake was determined every 2 weeks from the start of the
experiment (4-week-old mice) by deducting the total weight
of any remaining feed and the amount of spilled feed in each
cage from the weight of the feeder of each cage ﬁlled with a
constantamountof feedandthendividingeach diﬀerenceby
the numbers of days and the number of animals to calculate
a mean daily food intake per animal.
2.3. Changes in Body Weight and Visceral and Subcutaneous
Fat. Body weight was measured every week during the
period from the start of the study to the completion of the
study after 8 weeks (12-week-old). At 4 and 8 weeks, mice
were placed onanX-ray computedtopography(CT)scanner
for experimental animals, La Theta (ALOKA CO., LTD.,
Tokyo, Japan), under anesthesia with Nembutal (50mg/kg,
i.p.) and were scanned from the xiphisternum to sacrum at
1.5-mm intervals to determine visceral fat and subcutaneous
fat.
2.4. Measurement of the Plasma Components. At 8 weeks,
blood was drawn from the orbital venous plexus of the
mice under nonfasting conditions without anesthesia, with
a heparinized capillary tube. The collected blood was cen-
trifuged and plasma was obtained to perform the examina-
tions described below. Blood glucose level, total cholesterol
level (T-Cho), triglyceride level (TG), glutamic-oxaloacetic
transaminase (GOT) and glutamic-pyruvic transaminase
(GPT) levels were determined by measuring absorbance
using a Model 680 microplate reader (Bio-Rad, US),
using the following biochemical test kits: Glucose CII-Test-
Wako, Cholesterol E-Test-Wako, Triglyceride E-Test-Wako
and Transaminase CII-Test-Wako (all kitsused were made by
Wako Pure Chemical Industries), respectively. In addition,
blood was drawn from the caudal vena cava of the mice
under ether anesthesia 8 weeks after start of the study, with
a heparinized capillary tube, and plasma was obtained by
centrifugation and used to determine insulin levels, using
an insulin determination kit (ELISA method, Shibayagi Co.,
Ltd., Gunma, Japan) in a similar manner.
2.5. Glucose Tolerance Test. At 8 weeks, glucose was given
orally (p.o) to the mice after an 18h fast at a dose of
2g/kgandbloodglucosewasdeterminedimmediately before
administration of glucose (0min) and 30, 60, 120 and
180min after glucose administration. Blood samples were
drawn from the orbital venous plexus, and plasma was
obtained by centrifugation. The glucose level of each plasmaEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Analysis by three-dimensional HPLC of major chemical compounds in Salacia reticulata.
sample was determined ina similar manner to that described
in the previous section.
2.6. Blood Pressure. At 8 weeks, the blood pressure of each
mouse was measured using a noninvasive blood pressure
m e t e rB P - 9 8 A( S o f t r o n ,C o . ,L t d ,T o k y o ,J a p a n ) .E a c hm o u s e
was ﬁxed in a positioner THC-2 (Softron, Co., Ltd) while
body temperature was maintained at 37◦C, and blood
pressure at the base of the tail was determined by inserting
the tail up to its base into the tail cuﬀ.
2.7. Pain Test. The foot-pinch method as described by
Suzuki et al. [17] was used to investigate response to pain
sensation. At 8 weeks, the proximal part of the tarsus in
the metatarsal region of the hind limb was pinched with an
artery clip (BHO20R; pressure 300g: Bulldog Clamp, Johns
Hopkins,Tokyo,Japan),andthetimeuntilthemousereacted
and bit the clip on the hind limb was determined as a latent
reaction time until the mouse felt pain. The mean latent
reaction time of both hind limbs was regarded as the latent
reaction time of each individual animal.
2.8. Histopathological Examination of the Liver. At 8 weeks,
the mice were dissected to collect livers after drawing blood
from the inferior vena cava of 12-week-old mice under
ether anesthesia. After formalin ﬁxation of collected livers,
Hematoxylin and Eosin (HE)-stained sections were prepared
a n do b s e r v e du n d e ra no p t i c a lm i c r o s c o p e( ×40).
2.9. Statistical Analysis. The signiﬁcant diﬀerences were
evaluated using Dunnett’s multiple comparison test.
3.Results
3.1.FoodIntake. Nodiﬀerencesinfood intakewereobserved
between TSOD mice (4.5 ± 0.1g/1 mouse/day (5W)) and
TSNO mice [4.0 ± 1.3g/1 mouse/day (5W)].
3.2. Changes in Body Weight and Visceral and Subcutaneous
Fat
3.2.1. Growth Curve. The TSOD control group showed
signiﬁcant body weight gain compared with the TSNO
control group throughout the entire experimental period,
from the start to the completion of the study (Table 1).
In both TSOD and TSNO mice, Salacia extract-treatment
groups showed signiﬁcant and dose-dependent decreases in
the body weight within 1 week after the start of treatment,
and the 1% and 3% TSOD groups, in particular, showed
marked decreases in body weight.
3.2.2. Changes in Visceral and Subcutaneous Fat. Figure 2
shows the amount of both visceral and subcutaneous fat in
the TSOD control group increased signiﬁcantly compared
with the TSNO control group at 4 and 8 weeks after start
of the study, and the diﬀerences increased with time. On
the other hand, among the TSOD mice, the treatment
groups showed signiﬁcant, dose-dependent decrease in both4 Evidence-Based Complementary and Alternative Medicine
Table 1: The eﬀect of Salacia reticulata on the body weight of the TSOD and TSNO mice.
TSOD-C 1% SR-TSOD 3% SR-TSOD TSNO-C 1% SR-TSNO 3% SR-TSNO
0 week 22.2 ± 3.2 21.7 ± 2.9 21.8 ± 3.0 12.9 ± 1.4 12.6 ± 1.1 12.7 ± 1.2
4 weeks 39.7 ± 4.1∗ 34.1 ± 3.9∗ 28.1 ± 4.3∗ 31.2 ± 1.4# 28.9 ± 1.6# 26.1 ± 0.9#
8 weeks 47.4 ± 4.5∗ 38.0 ± 2.8∗ 30.6 ± 3.8∗ 34.3 ± 1.6# 31.0 ± 1.8# 30.1 ± 0.6#
Data represent the mean ± SD of the results in 6–9 animals.
∗P<. 05 (versus TSOD control); #P<. 05 (versus TSNO control).
visceral and subcutaneous fat compared with the TSOD
control group, and the diﬀerences increased with time.
Among TSNOmice, the treatment groups also showed dose-
dependent decrease in the amount of both visceral and
subcutaneous fat compared with the control group and the
diﬀerencesigniﬁcantin the3%Salacia extract-treated group.
3.3. Measurement of Plasma Components. The TSODcontrol
group showed signiﬁcantly higher levels of insulin, T-Cho
and TG than the TSNO control group, but no signiﬁcant
diﬀerences in blood glucose were observed between the
control groups (Figure 3). Between-group comparisons in
the TSOD cohort, the 1% and 3% treated group showed
dose-dependent decrease in levels of blood glucose, insulin
and T-Cho, compared to control group. The decrease in the
levels of blood glucose and insulin were signiﬁcant for 1%
treated-TSOD group. Similarly, among the TSNO cohort,
the 1% group showed a signiﬁcant decrease in T-Cho, while
the 3% group showed a signiﬁcant decrease in blood glucose
level.
3.4.GlucoseTolerance Test. TheTSODcontrolgroupshowed
signiﬁcantly higher blood glucose levels from 60 to 180 min
after glucose loading, compared with the time course of
changes in the blood glucose levels in the TSNO control
group, with signiﬁcant diﬀerences apparent at 120 and
180min after glucose loading, indicating a reduction in
glucose tolerance in the TSOD mice (Figure 4). Among
TSOD mice, both the 1%- and the 3%-treated groups
showed signiﬁcantdecreasein bloodglucoselevelscompared
to the control group from 60 to 180min after glucose
loading. Similarly, the 3%-treated TSNO group showed a
signiﬁcant decreasein bloodglucosecomparedrelativetothe
TSNO control group at 180min.
3.5. Blood Pressure. The TSOD control group showed sig-
niﬁcant elevations in SBP, DBP and MBP values, compared
with the TSNO control group (Table 2). In TSODmice, both
the 1%- and 3%-treated groups showed dose-dependent
suppression of SBP, DBP and MBP values, compared to
control group. The antihypertensive eﬀect was signiﬁcant in
each dose group. In the TSNO mice, only the 3%-treated
TSNO group showed signiﬁcant suppression of SBP, DBP
and MBP values, compared to control group.
3.6.Pain Test. The TSODcontrolgroupshowed signiﬁcantly
longer latent reaction time than the TSNO control group
(Table 3). Regarding this prolonged latent reaction time in
the TSOD control group, the 1% and 3%-treated groups
bothshowedsigniﬁcant,dose-dependentreductionsinlatent
reaction time. In contrast, there was little between-group
diﬀerence in TSNO mice in latent reaction time.
3.7. Histopathological Examination of the Liver. The TSOD
control group showed marked enlargement of hepatocytes
and fatty degeneration, due to accumulation of ﬁne lipid
droplets, compared to the TSNO control group (Figure 5).
In addition, inﬁltration of inﬂammatory cells and single-cell
necrosis were observed in the TSOD control group. Com-
pared to TSOD control group, enlargement of hepatocytes
was suppressed in a dose-dependent manner in the 1% and
3%-treated groups, and fatty degeneration of hepatocytes,
inﬁltration of inﬂammatory cells and single-cell necrosis
were also improved. In contrast, none of the TSNO mice
groups showed any changes in the liver. Among the liver
function test items, Salacia extract treatment did not aﬀect
GOT and GPT in either TSOD or TSNO mice (Figure 5).
4.Discussion
In this study, we compared the preventive eﬀects Salacia
extract on metabolic disorders, including obesity using
TSOD mice, a model of obesity with that of TSNO mice
that had not developed obesity and/or various symptoms
of metabolic syndrome (MS). Increase in body weight was
found to be signiﬁcantly higher in the TSOD groups than in
the TSNO groups, from the early stage of the experiment.
T h eT S O Dm i c eb e c a m em a r k e d l yo b e s e .I nb o t hT S O D
and TSNO mice, Salacia extract treatment was associated
with dose-dependent decrease in body weight with time.
At 8 weeks after initiation of treatment, body weight gain
was suppressed by approximately 36% in the 3%-treated
TSOD group compared to control, while body weight gain
was also suppressed in the TSNO groups, showing stronger
suppression of body weight gain in TSOD obese mice. Since
there were no diﬀerences in food intake between the groups
and the liver function tests showed no abnormal GOT and
GPT, it was suggested that the suppression of body weight
gain due to treatment was not caused by suppression of food
intake or a toxic eﬀect.
It is thought that obesity is mainly caused by fat
accumulation.TheTSODcontrolgroupshowedsigniﬁcantly
greater visceral and subcutaneous fat accumulation than the
TSNO control group, and the accumulation in each group
mostlyparalleledthetimecourseofbodyweightgain.Salacia
extract markedly suppressed both visceral and subcutaneous
fat accumulation in the TSOD mice and the suppression wasEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: The eﬀect of Salacia reticulata on the accumulation of adipose tissue in the TSOD and TSNO mice. (a) Computed topography
scanner. (b) Visceral fat. (c) Subcutaneous fat. Data represent the mean ± SD of the results in six to nine animals. ∗P<. 05 (versus TSOD
control); #P<. 05 (versus TSNO control); +P<. 05 (TSODcontrol versus TSNO control); pink zone: visceral fat; yellow zone: subcutaneous
fat.
Table 2: The eﬀect of Salacia reticulata on the blood pressure of the TSOD and TSNO mice at 8 weeks.
TSOD-C 1% SR-TSOD 3% SR-TSOD TSNO-C 1% SR-TSNO 3% SR-TSNO
SBP 107.6 ± 6.7+ 94.1 ± 5.6∗ 90.5 ± 8.7∗ 94.1 ± 5.6+ 93.8 ± 9.5 86.8 ± 9.6#
DBP 74.4 ± 7.3+ 67.0 ± 5.3∗ 54.7 ± 11.4∗ 67.0 ± 5.3+ 63.3 ± 7.6 55.5 ± 8.5#
MBP 85.4 ± 5.7+ 75.9 ± 5.1∗ 66.5 ± 10.0∗ 75.9 ± 5.1+ 73.3 ± 7.7 65.9 ± 8.2#
Data represent the mean ± SD of the results in 6–9 animals.
∗P<. 05 (versusTSODcontrol); #P<. 05 (versus TSNO control); +P<. 05 (TSOD control versus TSNO control); SBP, systolic blood pressure; DBP, diastoric
blood pressure; MBP, mean blood pressure.
Table 3: The eﬀect of Salacia reticulata on the peripheral neuropathy of the TSOD and TSNO mice at 8 weeks.
TSOD-C 1% SR-TSOD 3% SR-TSOD TSNO-C 1% SR-TSNO 3% SR-TSNO
7.5 ± 2.7+ 4.5 ± 2.3∗ 2.9 ± 0.4∗ 4.8 ± 2.7+ 4.4 ± 1.7 5.3 ± 1.3
Data represent the mean ± SD of the results in 6–9 animals.
∗P<. 05 (versus TSOD control); #P<. 05 (versus TSNO control); +P<. 05 (TSOD control versus TSNO control).6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀect of Salacia reticulata on the biochemical parameters of plasma in the TSOD and TSNO mice at 8 weeks. Data represent
the mean ± SD of the results in six to nine animals. ∗P<. 05 (versus TSOD control); #P<. 05 (versus TSNO control); +P<. 05 (TSOD
control versus TSNO control).
most notable when comparing the 3%-treated TSOD group
and the control group. It was suggested that the suppression
offat accumulationby Salacia extract was afactor in thesup-
pression of body weight gain. Furthermore, Salacia extract
also signiﬁcantly suppressed both visceral and subcutaneous
fat accumulation in the 3% TSNO group, compared to the
control group, showing similar results for body weight gain.
Yoshikawara et al. reported the anti-obesity eﬀect of Salacia
reticulata in Zucker fatty rats and SD rats fed a high-fat diet
[11]. Koshino et al. examined the eﬀect of Salacia extract
on the mice fed a high-fat diet, and reported that Salacia
extract suppressed visceral fat accumulation [22]. This study
alsoshowedthatSalaciaextractsuppressedbodyweightgain,
but it was suggested that the suppression of visceral and
subcutaneous fat accumulation largely contributed to the
anti-obesity eﬀect.
Since visceral fat accumulation is known to be a fun-
damental cause of various symptoms of MS, it is expected
that the suppression of visceral fat accumulation by Salacia
extract wouldpreventvarious disease statesfollowing insulin
resistance, and therefore the following investigation was
performed.
It is known that insulin resistance resulting from visceral
fat accumulation is involved in various metabolic disorders.
Compared to the TSNO control group, hyperinsulinemia
and abnormal glucose tolerance were observed in the TSOD
control group, suggesting that TSOD mice developed insulin
resistance. In the TSOD mice, Salacia extract treatment
decreased blood glucose levels and insulin levels, and
improved abnormal glucose tolerance in a dose-dependent
manner. In contrast, in the TSNO mice, the 3%-treated
group showed decreases in blood glucose levels and par-
tially signiﬁcant decreases in the glucose tolerance. It has
been reported that salacinol and kotalanol contained in
Salacia have an α-glucosidase inhibitory eﬀect comparable
to acarbose, which is used clinically for the inhibition of
postprandial hyperglycemia [8, 10], and it has been found
that 13-membered ring thiocyclitol, which was detected in
Salacia, also has a potent α-glucosidase inhibitory eﬀect
[23, 24]. It was suggested that decreased absorption ofEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Changes of the plasma glucose levels in the oral glucose test. Data represent the mean ± SD of the results in six to nine animals.
∗P<. 05 (versus TSOD control); #P<. 05 (versus TSNO control). Signiﬁcant diﬀerences were noted between the TSOD control mice and
TSNO control mice at 120 and 180min after the start of the oral glucose tolerance test.
glucose derived from dietary carbohydrates due to this α-
glucosidaseinhibitory eﬀectofSalacia maybeinvolvedin the
blood glucose-lowering eﬀects observed in both TSOD and
TSNO mice groups in this study. It has also been suggested
that the suppressive eﬀect of Salacia extract on visceral fat
accumulation contributed to the improved insulin resistance
in the TSOD mice groups. It has been reported that S.
reticulata improved hemoglobin A1c in patients with type 2
diabetes [25] and suppressed increases in blood glucose and
blood insulin levels [26] in clinical studies, and it is assumed
that S. reticulata improves glucose metabolism.
The TSOD control group showed signiﬁcant increases in
plasma T-Cho and TG, compared with the TSNO control
group, and the TSOD control group showed symptoms of
abnormal lipid metabolism. On histopathological examina-
tion of the liver, fatty degeneration was observed in the
TSOD control group. Salacia extract signiﬁcantly lowered T-
Cho levels in a dose-dependent manner and improved liver
degeneration in the TSOD mice. At the same time, Salacia
extract also lowered blood T-Cho levels in the TSNO mice
groups. Both TSOD and TSNO mice groups showed no
signiﬁcant diﬀerences in blood TG levels due to treatment
with Salacia extract. Salacia extract is known to increase
the activity of hormone-sensitive lipase involved in lipolysis
[26], and Huang et al. [27, 28]r e p o r t e dt h a tt r e a t m e n t
with S. oblonga,ap l a n tt h a ti sam e m b e ro ft h es a m e
species as S. reticulata, induced expression of peroxisome
proliferator-activated receptor (PPAR)-α regulatory genes
and protein expression (PPARα, CPT1, ACO), which are
involvedin β-oxidationintheliverinZuckerdiabetesrats. In
addition, it has been reported that polyphenolic constituents
contained in Salacia extract exhibit a lipolytic action by
inhibiting enzymes involved in lipid metabolism, such as
pancreatic lipase,lipoproteinlipaseandglucose-6-phosphate
ester dehydrogenase [11]. On the basis of the above ﬁndings,
this study suggests that Salacia extract decreases fatty weight
and improves degeneration of hepatocytes by acting to
facilitate lipolysis in the liver and adipocytes. In contrast, it
has been suggested that plasma TG levels are not improved
as a result of transfer of free fatty acids produced by lipolysis
from liver tissues and adipose cells to plasma. Since it
is known that accumulation of adipose tissues and fat in
the liver evoke insulin resistance, it was suggested that the
suppression of fat accumulation and reduction in hepatic
lipids due to Salacia extract treatment partially contributed
to improved insulin resistance.
On histopathological examination of the liver, gross
swelling of the liver was seen in the TSOD control group,
and the liver was yellowish-white in color. Histologically,
extensive fatty degeneration of hepatocytes due to accu-
mulation of ﬁne lipid droplets was found, and it was
considered that the liver had progressed to fatty liver. These
changes are similar to those found in the livers of patients
with Nonalcoholic Fatty Liver Disease (NAFLD) and were
considered to be aﬀected by diabetes. It is known that
human NAFLD progresses to nonalcoholic steatohepatitis
(NASH) by second hit of adipocytokines and inﬂammatory
cytokines [29]. In the TSOD mice groups, inﬁltration of
inﬂammatory cells includingneutrophils,single-cell necrosis
and hepatocellular swelling were also observed. In addition,
when feeding TSOD mice without treatment for a long
time, they develop liver tumors at high rates. Based on
these ﬁndings, it was considered that livers of the TSOD
control group appeared similar to that of livers in humans8 Evidence-Based Complementary and Alternative Medicine
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Figure 5:Eﬀect ofSalacia reticulata onliverhistology(×40) andliver function test. GOT denotes glutamateoxaloacetate transaminase;GPT
denotes glutamate pyruvate transaminase.
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the initial disease state in NASH. Salacia extract suppressed
these changes and it has been inferred that the suppression
was mainly caused by decreased body fat and improvement
of diabetes. While it cannot be concluded deﬁnitively that
Salacia extract suppresses the development of liver tumors
in the TSOD control group, Salacia extract may improve
human NASH.
The eﬀect on hypertension, one of the symptoms of
MS, was examined. SBP, DBP and MBP levels in the 12-
week-old TSOD control group at the completion of the
experiment were signiﬁcantly higher than those in the TSNO
control group, indicating that the TSOD control group
was hypertensive. Salacia extract signiﬁcantly decreased the
blood pressure in TSOD mice in a dose-dependent manner,
indicating that Salacia extract has a preventive eﬀect on
hypertension, one ofthesymptoms ofMS. Moreover, Salacia
extract also showed a signiﬁcant hypotensive eﬀect in the
3% Salacia extract TSNO group. Hung et al. reported
that S. oblonga root extract suppressed angiotensin II-
stimulated hypertrophic responses and protein synthesis
in heart-derived H9c2 cells and angiotensin II-accelerated
hyperplasia in rat cardiac ﬁbroblasts [30]. Hung et al.
[31] also reported that S. oblonga decreased cardiac AT1
receptors. Since angiotensin II elevates blood pressure, it was
suggested that angiotensin II was involved in the decreases
in blood pressure due to Salacia extract treatment observed
in this experiment. Additionally, visceral fat accumulation
maycontributetothedevelopmentofhypertension inTSOD
mice, and it was also suggested that the suppression of
visceral fat accumulation was involved in the Salacia extract-
treatment-associated decrease in blood pressure.
We have already reported that peripheral neuropathy
develops as a diabetic complication in TSOD mice [16, 31–
33]. The latent reaction time was signiﬁcantly longer in the
TSOD control group than in the TSNO control group, and
it was suggested that peripheral neuropathy had developed
in the TSOD control group. In addition, Salacia extractEvidence-Based Complementary and Alternative Medicine 9
treatment signiﬁcantly decreased latent reaction time in the
TSODmice groupsin a dose-dependentmanner. It is known
that advanced glycation end products (AGEs) are produced
in diabetic hyperglycemia and that these AGEs contribute
to diabetic peripheral neuropathy. It was suggested that
the hypoglycemic eﬀect of Salacia extract shown in this
study prevented peripheral neuropathy by suppressing AGE
production.
In conclusion, it may be stated that Salacia extract treat-
ment decreases body weight, visceral and subcutaneous fat
accumulation and blood glucose, improvement of abnormal
lipid metabolism, fatty liver and enlarged liver. A decrease in
blood pressure and improvement of peripheral neuropathy
inTSODmicesuggestedthat Salaciaextract hasthepotential
to prevent the development of the major disease states seen
inMS.Furthermore,Salaciaextract treatmentwasassociated
with suppression ofbody weight gain, decreases in plasma T-
Cho levels and decreased blood pressure in TSNO mice, the
control mice, suggesting that Salacia extract treatment at the
level used in this study has utility in healthy subjects.
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